Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section ...

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...

Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more ...

Kelsi Victorian, 30, has been in and out of the hospital her whole life dealing with a disease that affects millions in the world.

Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...

Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 10.59%, which has investors questioning if this is right time to buy.

Certain subsets of immune NK cells were altered in the blood of people with ALS, and could serve as therapeutic targets, a ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases; Initial data for NKX ...

About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...

With a storied history in vaccine development, India's Bharat Biotech is shaking things up and answering the call of advanced ...